Condition: Acute Ischemic Stroke · Sponsor: First Affiliated Hospital of Harbin Medical University
The goal of this clinical trial is to explore the changes in the expression levels of inflammatory factors before and after the early treatment of Human Urinary Kallidinogen (HUK) in the acute ischemic stroke. It will also learn about the correlation between inflammatory factors and AIS prognosis, in order to clarify the efficacy and safety of Urinary Kallidinogen in the acute phase of AIS.
This description comes directly from the study's public registry record.
Zhongling Zhang · +8613503615988 · zhang777hyd@163.com
shanshan yang · +8613845104003 · yangshanshan81@163.com
Always discuss trial participation with your own doctor first.
| Zhongling Zhang | Harbin, Heilongjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06696703